Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

were randomized on a 1:1 ratio to either Vidaza of the CCR with stratification by FAB subtypes (RAEB or RAEB-T) and IPSS subgroups (INT-2 or HIGH). Investigators selected the CCR option for each individual patient prior to randomization. The primary objective of the trial was to demonstrate superiority in survival of Vidaza plus best supportive care versus CCR plus best supportive care in higher-risk MDS patients. Secondary objectives of the trial included transfusion independence, hematologic status, hematologic response and hematologic improvement, episodes of infections requiring intravenous antibiotics, time to relapse after complete response (CR) or partial response (PR), time to disease progression, time to transformation to AML, time to transformation or death from any cause, safety and toxicity and pharmacoeconomics.

About Vidaza

In May 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza, the first in a new class of drugs called demethylation agents, for treatment of all five MDS subtypes, which include both low-risk and high-risk patients. These subtypes include: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of Vidaza required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of Vidaza cause the death of rapidly dividing cells,
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  MEI Pharma, Inc. (Nasdaq: MEIP ), ... novel therapies for cancer, today announced results for its ... - http://photos.prnewswire.com/prnh/20140805/133834 "Despite a ... pleased with how the Company is positioned entering fiscal ... President and Chief Executive Officer of MEI Pharma. "While ...
(Date:9/2/2015)... , Sept. 2, 2015 Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today that ... both the FBR Second Annual Healthcare Conference and BioCentury ... FBR Second Annual Healthcare Conference Date:  ... Boston No presentation, investor meetings only ...
(Date:9/2/2015)... and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... commercialization of new cancer therapies, today announced that ... Comparison of the Mechanisms and Cytotoxic Activity of ... Harboring Wild-type and Mutant p53," at the ...
Breaking Medicine Technology:MEI Pharma Reports Fiscal Year 2015 Results 2MEI Pharma Reports Fiscal Year 2015 Results 3MEI Pharma Reports Fiscal Year 2015 Results 4MEI Pharma Reports Fiscal Year 2015 Results 5MEI Pharma Reports Fiscal Year 2015 Results 6MEI Pharma Reports Fiscal Year 2015 Results 7Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 2DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 3DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 4
... National Stem,Cell Holding, Inc. (OTC: NHGI.PK), today ... Jacob Cohen, have discovered biomaterial derived from,non- embryonic ... in,various wound care applications. On July 26, ... embryonic stem cell lines, Michael and Jacob Cohen ...
... Aug. 14 StatSure,Diagnostic Systems, Inc. (OTC Bulletin Board: ... "barrel- test" format for the detection of,antibodies to HIV-1/2 ... trials needed for a CLIA waiver application and that ... & Drug Administration (FDA) for,their review. The Company believes ...
Cached Medicine Technology:National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 2National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 3CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 2CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 3
(Date:9/2/2015)... , ... September 02, 2015 , ... Ericson is a ... Education Director for HCPro and Associate Director of Education for the Association for Clinical ... CDI and ICD-10 for CDI Boot Camps. She serves as a CDI subject matter ...
(Date:9/2/2015)... ... ... Every year at this time, students prepare to go back to school. ... the academic workload confronting them. They just don’t have the skills needed to do ... students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job of ...
(Date:9/2/2015)... City, KS (PRWEB) , ... September 02, 2015 , ... ... opened its newest office in Kansas – its Johnson County location. Amada ... in healthcare. Mike has a registered nurse background and spent over 20 years in ...
(Date:9/2/2015)... North Las Vegas, NV (PRWEB) , ... September ... ... in Las Vegas and Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as ... the largest medical auction house in the world, selling more than 100,000 pieces ...
(Date:9/2/2015)... ... 02, 2015 , ... On September 9, 2015, over 27,000 people from all ... single-company convention to date for the state of Utah. , “We are thrilled with ... states David Stirling, doTERRA CEO. “One of the most exciting elements of our convention ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2
... Dec. 1 The Kerlan Jobe Orthopaedic Clinic, a sports ... United States $3 million to settle allegations that it received ... , The settlement resolves allegations ... of stock option grants, donations to the Kerlan Jobe Foundation, ...
... A scientist who broadened the understanding of how we experience ... -- has won the 2010 University of Louisville Grawemeyer Award ... University in Montreal, was selected for the award from among ... of injury but instead in their brain through a pathway ...
... more likely, British study finds , TUESDAY, Dec. 1 (HealthDay ... to deliver a very preterm baby than more affluent women, ... British study shows. , The University of Leicester research team ... the association between economic status and preterm birth. , For ...
... on computed tomography (CT) imaging of changes in tumors ... bevacizumab may have the potential to predict overall survival, ... of JAMA . The addition of ... with improved survival in patients with stage IV colorectal ...
... ... ... largest national HIV non-profit organizations, is changing its name to HealthHIV and launching a new ... promote the organization’s new vision and expanded capabilities and reach. , , , , ,“HealthHIV ...
... With employee benefit choices becoming more complex, a growing ... during open enrollment season, according to a new survey by ... employers who offer these tools believe they lead employees to ... survey, 45 percent of companies offered employees self-service decision tools ...
Cached Medicine News:Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:Scientist Who Helps Explain Pain Wins Grawemeyer Award 2Health News:More Preemies Born Among the Poor 2Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2Health News:National HIV Non-Profit Announces New Name 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: